Neopterin as a marker of response to antiviral therapy in hepatitis C virus patients.
Neopterin as a marker of response to antiviral therapy in hepatitis C virus patients.
复制标题
DOI：
10.1155/2012/619609
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Summergrad P
中科院分区：
文献类型：
--
作者：
Oxenkrug GF;Requintina PJ;Mikolich DL;Ruthazer R;Viveiros K;Lee H;Summergrad P
预测丙型肝炎病毒(丙型肝炎病毒)的抗病毒治疗效果对患者的福祉和医疗费用都具有重要意义。干扰素刺激基因(干扰素-SGS)在肝脏的表达被认为是抗病毒治疗反应的一个标志。干扰素-SGS编码鸟苷三磷酸环水解酶1(GTPCH)，它是蝶类药物生物合成的限速酶。新喋呤是GTPCH催化反应的稳定副产物，被用作干扰素诱导GTPCH激活的标志物。我们推测，对新喋呤浓度的评估可能会预测抗病毒治疗的反应。用聚乙二醇化干扰素联合利巴韦林治疗260例丙型肝炎患者，评价新喋呤的血药浓度。持续病毒学应答患者的平均和中位数治疗前新喋呤浓度低于无应答患者。即使在控制了 基因状态后，治疗前新喋呤水平为16 /L的患者的应答率也是新喋呤水平为16≥nmol/L的患者的两倍。我们的研究提示，新喋呤的治疗前水平可作为预测丙型肝炎患者抗病毒治疗疗效的快速、经济的指标用于临床实践。
Predicting the efficacy of antiviral treatment of hepatitis C virus (HCV) is of importance for both patient well-being and health care expense. The expression of interferon-stimulated genes (IFN-SGs) in the liver was suggested as a marker of response to anti-viral therapy. IFN-SGs encode the guanosine triphosphate cyclohydrolase 1 (GTPCH), a rate-limiting enzyme of pteridines biosynthesis. Neopterin, a stable byproduct of GTPCH-catalyzed reaction, is used as a marker of interferon-induced GTPCH activation. We hypothesized that assessment of neopterin concentrations might predict the response to antiviral therapy. Neopterin concentrations were evaluated in 260 HCV patients treated by pegylated interferon combined with ribavirin. Mean and median pretreatment neopterin concentrations were lower in patients with sustained virological response than in nonresponders. The rate of response was twofold higher among patients with pretreatment neopterin levels <16 nmol/L than in patients with neopterin levels ≥16 nmol/L, even after controlling for HCV genotype status. Our study suggests that the pretreatment level of neopterin might be used in routine clinical practice as rapid and cost-effective marker to predict the response to antiviral therapy in HCV patients.